Changing profile in the use of anti-asthma drugs

Pharmacoepidemiology and Drug Safety

Volumn 8, Issue 6, 1999, Pages 385-394

  Bell, H M ^a   Mcelnay, J C ^a   Hughes, C M ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Asthma; Defined daily dose; Drug utilization

Indexed keywords

AMINOPHYLLINE; ANTIALLERGIC AGENT; ANTIASTHMATIC AGENT; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUTICASONE; GENERIC DRUG; GLUCOCORTICOID; IPRATROPIUM BROMIDE; ISOPRENALINE; NEDOCROMIL SODIUM; ORCIPRENALINE; OXITROPIUM BROMIDE; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; XANTHINE;

ARTICLE; ASTHMA; CLINICAL PROTOCOL; DATA ANALYSIS; DRUG DELIVERY SYSTEM; DRUG UTILIZATION; DRY POWDER; HUMAN; INHALATIONAL DRUG ADMINISTRATION; POWDER INHALER; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; UNITED KINGDOM;

EID: 0032744362     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1557(199910/11)8:6<385::AID-PDS450>3.0.CO;2-3     Document Type: Article

References (32)

1. Department of Health. Asthma. An Epidemiological Overview, HMSO, London, 1995.
2. National Asthma Campaign. National Asthma Audit. London, 1996.
3. British Thoracic Society. Guidelines for asthma management. Br. Med. J. 1990; 301: 651-653, 797-800.
4. British Thoracic Society. Guidelines for asthma management. Thorax 1993; 48: S1-S24.
5. British Thoracic Society. Guidelines for asthma management. Thorax 1997; 52: S1-S21.
6. Duff, C. and Duerden, M. Performance indicators for asthma prescribing. Prescriber 1997; 8: 62-64.
7. Medicines Resource Centre. Inhalation devices in the treatment of asthma. MeReC Bull. 1993; 4:.
8. Medicine Resource Centre. Inhaler devices: an update. MeReC Bull. 1995; 6:.
9. British Thoracic Society. Current best practice for nebuliser treatment. Thorax 1997; 52(Supplement 2).
10. Maxwell, M., Heaney, D., Howie, J. G. R. and Noble, S. General practice fundholding: observations on prescribing patterns and costs using the defined daily dose method. Br. Med. J. 1993; 307: 1190-1194.
11. Dowell, J. S., Snadden, D. and Dunbar, J. A. Changing to generic formulary: how one fundholding practice reduced prescribing costs. Br. Med. J. 1995; 310: 505-508.
12. Williamson, I. J., Reid, A., Monie, R. D. H., Febberty, A. G. and Rimmer, E. M. Generic inhaled salbutamol versus branded salbutamol. A randomised double blind study. Postgrad. Med. J. 1997; 73: 156-158.
13. Pearson, M., Lewis, R. and Watson, J. et al. Generic inhalers for asthma. Br. Med. J. 1994; 309: 1440.
14. WHO Collaborating Centre for Drug Statistics Methodology. ATC index with DDDs. WHO, Norway, 1997.
15. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for DDDs. 2nd edn, WHO, Norway, 1993.
16. Wertheimer, A. I. The defined daily dose system (DDD) for drug utilization review. Hosp. Pharm. 1986; 21: 233-234, 239-241, 258.
17. Serradell, J., Bjornson, D. C. and Hartzema, A. G. Drug utilisation study methodologies: national and international perspectives. Drug Intell. Clin. Pharm. 1987; 21: 994-1001.
18. Merlo, J., Wessling, A. and Melander, A. Comparison of dose standard units for drug utilisation studies. Eur. J. Clin. Pharmacol. 1996; 50: 27-30.
19. Campbell, M., Bateman, D. N., Roberts, S. J. and Smíth, J. M. Appropriate prescribing in asthma. Br. Med. J. 1995; 310: 1069.
20. Jackevicius, C. A. and Chapman, K. R. Prevalence of inhaled corticosteroid use among patients with chronic obstructive pulmonary disease: survey. Annal Pharmacother. 1997; 31: 160-164.
21. National Prescription Pricing Authority. Asthma Treatment and Inhalers, 1997.
22. Jenkins, M. A., Hurley, S. F., Bowes, G. and McNeil, J. J. Use of anti-asthma drugs in Australia. Med. J. Aust. 1990; 157: 323-328.
23. Jacobson, G. A. and Peterson, G. M. Prescribing trends for anti-asthma drugs in Tasmania following the National Asthma Campaign. J. Clin. Pharm. Ther. 1996; 21: 317-324.
24. Burr, M. L. Is asthma increasing? J. Epidemiol. Commun. Health 1987; 41: 185-189.
25. Anderson, H. R. Epidemiology of asthma. Br. J. Hosp. Med. 1992; 47: 99-104.
26. Ninan, T. K., Russell, D. and Russell, G. Increasing prevalence of respiratory symptoms and atrophy in Aberdeen schoolchildren: evidence from two surveys. Br. Med. J. 1992; 304: 873-875.
27. Bosco, L. A., Knopp, D. E., Gerstman, B. and Graham, C. F. Asthma drug therapy in the United States, 1972 to 1985. J. Allergy Clin. Immunol. 1987; 80: 398-402.
28. Hallas, J. and Hansen, N. C. Individual utilization of anti-asthma medication by young adults: a prescription database analysis. J. Intern. Med. 1993; 234: 65-70.
29. Audit Commission. A Prescription for Improvement. Towards More Rational Prescribing in General Practice. HMSO, London, 1994.
30. Johnston, I. D. A. Theophylline in the management of airflow obstruction. Difficult drug to use, few clinical indications. Br. Med. J. 1990; 300: 929-931.
31. Gaist, D., Hallas, J., Hansen, N. C. and Gram, L. F. Are young adults with asthma treated sufficiently with inhaled steroids? A population-based study of prescription data from 1991 to 1994. Br. J. Clin. Pharmacol. 1996; 41: 285-289.
32. Smith, J. M. and Bateman, D. N. Treating asthma. Clinical efficacy and safety of generic inhalers is well established. Br. Med. J. 1995; 310: 254.